N/A
N=18
Vagal Nerve Stimulation for Post COVID Fatigue
Post COVID Syndrome · Fatigue · Headache
Bottom Line
View on ClinicalTrials.gov: NCT05445427 ↗Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcome: Primary: Change in Post-COVID Functional Status Score — 0.1; 0.3 units on a scale — p=0.544
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- vagal nerve stimulator (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Mar 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Post-COVID Functional Status Score |
0.1; 0.3 | 0.544 |
| SECONDARY Change in PROMIS Fatigue Scale T Score |
-5.4; -1.9 | 0.292 |
Summary
The purpose of this study is to evaluate the impact of vagal nerve stimulation on patients with post COVID syndrome who have fatigue and headache.
Eligibility Criteria
Inclusion Criteria
- Presence of fatigue and post exertional malaise.
- Presence of headache
- Clinical diagnosis of post COVID syndrome.
- They have consented to participate in the study
- They have the ability to participate in all aspects of the study.
Exclusion Criteria
- Pregnant.
- Prior adverse reaction to 14FDG.
- Active implantable medical device e.g. pacemaker, hearing aid implant
- Metallic device e.g. stent, orthopedic hardware in neck
- Using another electronic device at the same time e.g. TENS, mobile phone.
- Any other condition deemed exclusionary by the study principal investigator
Data sourced from ClinicalTrials.gov (NCT05445427). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.